SLU-PP-332 vs BAM15: burning fuel is not the same as getting fit

The phrase “exercise in a pill” makes two promises sound like one: spend more energy, and become a fitter organism. SLU-PP-332 and BAM15 are interesting precisely because they force those promises apart. One changes the instructions the cell reads. The other changes how efficiently the mitochondrion turns fuel into usable energy.

These are not imaginary effects built entirely from testimonials. SLU-PP-332 has mouse endurance data, not just a colorful pathway diagram. BAM15 has mouse body-composition and insulin-sensitivity results, not just a test tube consuming oxygen. The mistake is not taking the science seriously. It is treating the next steps in drug development as if they have already happened.

They belong beside this site’s mitochondrial peptide coverage as a contrast, not a classification. Neither is a peptide hormone or a mitochondrial-derived peptide. A shared destination in energy metabolism does not make small molecules, endogenous signals, and membrane-targeting peptides interchangeable.

SLU-PP-332 is a synthetic agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ, with the greatest potency at ERRα in the reported assays. These are nuclear receptors involved in regulating metabolic gene expression. The name is misleading if you read it as estrogen therapy: estrogen-related receptors are not the classical estrogen receptors and do not share their estrogen-binding behavior. The Billon metabolic study explains that distinction.

The attractive idea is to activate part of the transcriptional machinery recruited by aerobic exercise: genes involved in oxidative metabolism and the capacity to use fuel. In Billon and colleagues’ 2023 ACS Chemical Biology paper, SLU-PP-332 increased oxidative muscle fibers and enhanced endurance in mice. ERRα was necessary for the reported endurance effect. That is stronger evidence than saying a compound merely “supports mitochondria.”

But the demonstrated claim is specific: pharmacological activation produced an exercise-associated program and selected functional effects in mice. It did not establish that a human taking the compound gains the integrated adaptations of training, or that more receptor activation is always better. A pathway can participate in exercise without containing everything exercise does.

The follow-up metabolic-syndrome paper, published online in 2023 and in the February 2024 journal issue, reported increased energy expenditure and fatty-acid oxidation, with reduced fat accumulation and beneficial metabolic changes in mouse obesity models. The appetite-independent angle is part of what makes the work worth following.

Read past the abstract, though. Chow-fed mice did not show improved glucose metabolism. In diet-induced obesity, the investigators acknowledged conflicting insulin-sensitivity findings: favorable fasting measures did not come with an improvement in the insulin-tolerance test. The discussion also notes that ERRα deletion and some inverse agonists have produced favorable metabolic phenotypes in other experiments. “Turn ERR up, fix metabolism” is not a universal rule.

The experiments used small groups of male mice over short periods. Less fat gained in one model and reversal of existing obesity in another are different outcomes. Neither tells us what happens in a trained human, across years of exposure, or alongside other metabolic drugs. These limitations do not erase the positive results. They define what the next study must resolve.

There is a detail in the SLU-PP-332 story that rarely survives the trip to a product page: it is not orally bioavailable. A compound that has to be injected into the abdomen to work is a laboratory instrument, not a pill. The interesting part of the last three years is the chemistry that went looking for a version you could swallow.

That search produced SLU-PP-915. In Hampton and colleagues’ 2023 European Journal of Medicinal Chemistry paper, a structure-based design effort starting from the known acyl hydrazide agonist GSK-4716 yielded a series of 2,5-disubstituted thiophenes. The move that matters is small and elegant: the phenol or aniline group could be replaced with a boronic acid, which held the agonist activity while improving metabolic stability in microsomal assays. SLU-PP-915 was the compound that came out of that swap, and it raised the expected ERR target genes in cells and in animals.

The payoff arrived in Billon and colleagues’ January 2026 JPET paper. Given by injection, 915 improved running distance and duration about as much as 332 did. Given by mouth, it kept comparable efficacy once the investigators adjusted for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding treadmill running depending on which muscle was sampled.

The cardiac work is the other reason to take the series seriously. In Xu and colleagues’ 2024 Circulation study, both 332 and 915 improved ejection fraction, reduced fibrosis, and increased survival in a mouse pressure-overload heart failure model, without changing cardiac hypertrophy. Genetic dependency experiments pointed to ERRγ as the main mediator. That is a more demanding experimental standard than a gene-expression panel, and it is the kind of result that moves a molecule toward development.

None of which changes the evidence grade. Everything above is rodent. No human intervention study or trial registration for SLU-PP-915 was identified in this review. Oral bioavailability in mice is a solved chemistry problem, not a demonstrated human drug. And the disclosures deserve reading: SLU-PP-915 is covered by Saint Louis University intellectual property with Thomas Burris as an inventor, and Burris holds stock in Myonid Therapeutics and Pelagos Pharmaceuticals, both developing ERR agonists.

One of the six papers mentioning SLU-PP-915 is not pharmacology at all. In a 2026 Rapid Communications in Mass Spectrometry study, researchers at the German Sport University Cologne and the European Monitoring Center for Emerging Doping Agents characterized both 332 and 915 by liquid chromatography and high-resolution tandem mass spectrometry, then mapped what human liver preparations do to them.

The two compounds behaved differently. SLU-PP-332 produced nine metabolites, six Phase-I and three Phase-II conjugates. SLU-PP-915 produced only Phase-I products, seven in total, three of which the team confirmed by chemical synthesis and NMR. The stated purpose is blunt: to help uncover illicit use of these compounds as performance-enhancing substances.

That paper is worth more than its citation count suggests. A detection assay is usually built because a laboratory expects to find something in a sample. Its existence says these molecules are already circulating outside the research setting, years ahead of any human trial. It is also the clearest available answer to anyone treating an ERR agonist as a supplement: sports testing programs classify it as a doping candidate, and now they can see it.

Mitochondria use fuel oxidation to build a proton gradient across their inner membrane. ATP synthase uses that gradient to make ATP, the cell’s immediately usable energy currency. A protonophore provides another route for protons to cross the membrane. Some of the energy that could support ATP synthesis is dissipated instead, so maintaining ATP production can require more fuel oxidation.

That is mitochondrial uncoupling. BAM15 is a synthetic small-molecule protonophore, not an ERR agonist. In plain language: SLU-PP-332 changes part of the metabolic program; BAM15 makes energy conversion less tightly coupled. Calling both “mitochondrial boosters” hides the most important difference.

In Alexopoulos and colleagues’ 2020 Nature Communications study, BAM15 reduced adiposity in mice without reducing food intake or lean mass under the tested conditions. Liver fat improved, and hyperinsulinemic-euglycemic clamp experiments supported improved insulin sensitivity in multiple tissues. Those clamp measurements are a substantive physiological result, not a marketing synonym for feeling more energetic.

The same paper reported no detected increase in body temperature or adverse changes in selected blood markers under its experimental conditions. That is encouraging preclinical tolerability. It is not a demonstrated human therapeutic window, and it does not mean arbitrarily high exposure is harmless. Solubility and formulation constrained the upper-exposure experiments; transient lethargy at the upper end could not be clearly separated from the thick preparation used for administration.

DNP, or 2,4-dinitrophenol, is the historical warning attached to uncoupling: a drug can increase energy expenditure and still have a dangerously narrow separation between desired and toxic effects. The BAM15 paper explicitly addresses that drug-development problem and describes BAM15 as structurally unrelated to DNP.

Two easy conclusions are wrong. “All uncouplers are exactly DNP” ignores chemistry, distribution, and exposure. “BAM15 is DNP without the danger” converts a mouse comparison into a human safety claim. The credible position is more demanding: newer compounds may improve the therapeutic window, but that window must be measured for each molecule and formulation.

Normal temperature in a mouse experiment cannot rule out all cardiac, hepatic, reproductive, or chronic risks in humans. Nor would a normal reading on a home thermometer or wearable certify safety. Absence of a particular toxicity signal is not the same as a complete safety profile.

A blanket dismissal of uncoupling would miss a real clinical development: HU6, a different compound metabolized to DNP, has entered randomized human studies. In a phase 2a study in adults with fatty liver disease and high BMI, it reduced MRI-measured liver fat. Flushing, diarrhea, and palpitations were reported; no serious treatment-emergent adverse events were reported in that study. This was human proof of concept for that strategy, not a trial of BAM15.

The more revealing result for the exercise claim came from the 2025 HuMAIN-HFpEF trial in people with obesity-related heart failure with preserved ejection fraction. HU6 reduced weight and fat mass without significant muscle-mass loss, but did not significantly improve peak oxygen consumption, six-minute walking distance, or the quality-of-life score. Serious adverse events occurred in both groups, including one death; investigators judged them unrelated to treatment.

That small trial does not prove uncoupling can never improve function. The investigators called for larger, longer studies. It does demonstrate why fat loss and fitness need separate endpoints. It is also not a negative trial of SLU-PP-332: a different molecule, mechanism, and patient population cannot settle its prospects.

The combination pitch practically writes itself: switch on the machinery with SLU-PP-332, then increase fuel expenditure with BAM15. It is an intelligible hypothesis. It is not demonstrated synergy. A stack would need to outperform each compound alone on a defined endpoint, with exposure, interaction, and safety measurements collected in the same experiment.

This review identified no controlled primary study validating that combination. Whether the effects are additive, redundant, counterproductive, or intolerable cannot be decided by drawing two arrows toward “fat burning.” A mechanism diagram also cannot establish compatibility with a GLP-1 drug, a stimulant, or strenuous training.

There is consequently no evidence-based human dose, cycle, or timing schedule to offer for either compound or their combination. Converting a mouse exposure into a human-looking number would not fill the missing pharmacokinetic and toxicology work. A vendor purity certificate, even if accurate about chemical identity, would not fill it either.

• Exact-compound human exposure data. A characterized formulation, measured pharmacokinetics, and monitored tolerability, rather than assuming an online product behaves like laboratory material.
• Endpoints that match the promise. Body composition and insulin sensitivity for metabolic claims; measured exercise capacity and patient function for fitness claims. One is not a substitute for the other.
• Enough follow-up to see the trade-offs. Durability, discontinuation, organ safety, and adverse events across a broader population, not just a favorable short experiment.
• Actual combination experiments. Comparison with each agent alone before claiming a stack is synergistic, let alone safe for people.

The strongest case for these molecules is not that the gym has become obsolete. It is that researchers may be able to treat aspects of metabolic disease through pathways distinct from appetite suppression. That remains worth investigating even if no compound ever replaces a workout.

If you have already used an unapproved product, tell your clinician the exact name, source, other substances, and timing rather than calling it a peptide supplement. Seek emergency care for severe symptoms such as chest pain, collapse, confusion, or overheating. Those are general emergency warning signs, not a validated BAM15 or SLU-PP-332 toxicity checklist; feeling fine does not establish safety.

The conclusion is neither “miracle” nor “fake.” These are genuine preclinical tools with unanswered clinical questions. Spending more fuel is one biological achievement. Becoming fitter, and doing either safely in a human, are separate achievements still to prove.

What is the difference between SLU-PP-332 and BAM15?

SLU-PP-332 activates estrogen-related receptors, changing an exercise-associated gene program. BAM15 is a mitochondrial protonophore that reduces the coupling of fuel oxidation to ATP production. Both can increase fuel use in experimental systems, but they do so through different mechanisms.

Are SLU-PP-332, SLU-PP-915 and BAM15 peptides?

No. All three are synthetic small molecules, not amino-acid-chain peptides. They are covered here as a comparison with mitochondrial peptide biology, not as members of the mitochondrial-derived peptide family.

Have SLU-PP-332 or BAM15 been tested in human clinical trials?

Our September 15, 2026 literature and ClinicalTrials.gov searches identified no published human intervention studies or registered trials for these exact names, including BAM-15. This does not exclude unpublished work or trials under other identifiers. Human trials of HU6 concern a different compound and cannot establish BAM15 safety.

Can SLU-PP-332 replace exercise?

It induced an exercise-associated gene program and improved endurance in mice. Those results do not establish human exercise replacement. Selected metabolic or endurance outcomes are not evidence that a drug reproduces the full effects of training.

Is BAM15 a safe version of DNP?

That description goes beyond the evidence. BAM15 is structurally different from DNP and showed encouraging tolerability in mouse experiments, including no detected rise in body temperature under the tested conditions. A human therapeutic window and long-term safety have not been established.

What is SLU-PP-915 and how is it different from SLU-PP-332?

SLU-PP-915 is a chemically distinct pan-ERR agonist from the same laboratory lineage, built around a boronic acid group that improved metabolic stability. Its practical difference is oral bioavailability: SLU-PP-332 lacks it, while 915 retained comparable efficacy in mice when given by mouth, adjusted for systemic exposure. Both remain preclinical.

Has SLU-PP-915 been tested in humans?

No published human intervention study or ClinicalTrials.gov registration for SLU-PP-915 was identified in our September 15, 2026 searches. All efficacy evidence is from rodent experiments. Anti-doping laboratories have published detection methods for it, which reflects expected non-clinical use rather than clinical testing.

Does SLU-PP-915 replace exercise?

The 2026 JPET study points the other way. Its notable result was that 915 synergized with exercise training to further increase Ddit4 and mitochondrial gene expression, meaning the strongest effect came in combination with training rather than as a substitute for it.

Can you stack SLU-PP-332 with BAM15?

No controlled evidence validating the combination was identified in this review. Different mechanisms do not demonstrate synergy, compatibility, or safety. There is no evidence-based human stack, dose, or timing schedule to recommend.

• Billon et al. Synthetic ERRα/β/γ agonist and exercise capacity. ACS Chemical Biology (2023).
• Billon et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. JPET (2024 issue; online 2023).
• Alexopoulos et al. BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications (2020).
• Hampton et al. New chemical series of potent pan-ERR agonists, identification of SLU-PP-915. European Journal of Medicinal Chemistry (2023).
• Billon et al. An orally active ERR agonist, SLU-PP-915, enhances aerobic exercise capacity. JPET (2026).
• Xu et al. Novel pan-ERR agonists ameliorate heart failure. Circulation (2024).
• Möller et al. In vitro metabolism and analytical characterization of SLU-PP-332 and SLU-PP-915. Rapid Communications in Mass Spectrometry (2026).
• Noureddin et al. HU6 in fatty liver disease and high BMI. Lancet Gastroenterology & Hepatology (2023).
• Pandey et al. HuMAIN-HFpEF randomized clinical trial. JAMA Cardiology (2025).

Literature and ClinicalTrials.gov checked September 15, 2026. Exact-name searches for SLU-PP-332, SLU-PP-915 and BAM15 (also BAM-15) identified no registrations. No published human intervention studies for either exact compound were identified. This is not an exhaustive audit of every international registry and cannot exclude unpublished studies or other identifiers.

No retraction or expression-of-concern notice was identified for the foundational Billon, Hampton, Xu and Alexopoulos papers in the publication records checked. That is a publication-status check, not independent validation of the raw data. The studies include disclosed commercial interests: ERR-therapeutic company equity and inventorship on the SLU-PP-332 and SLU-PP-915 work, including Myonid Therapeutics and Pelagos Pharmaceuticals, biotechnology interests in the BAM15 work, and industry funding or relationships in the HU6 studies. These disclosures warrant attention, not automatic dismissal.